SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody [Yahoo! Finance]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Yahoo! Finance
The agreement will leverage SciNeuro's proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market. Both companies will jointly oversee early-stage development of the antibody candidates. Following the initial stages, Novartis will assume responsibility for all further product development and commercialisation worldwide. Under the agreed terms, SciNeuro will receive an upfront payment of $165m. The company may also receive research funding, along with up to $1.5bn in potential development, regulatory and commercial milestones. Tiered royalties will also be available. Completion of the transaction is anticipated in the first half of 2026, subject to the end or waiver of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period and fulfilment of customary closing conditions. SciNeuro founder and CEO Min Li said: “The anti-amyloid programme represents one of SciNeur
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences (RNA) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=RNA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to "hold".MarketBeat
- Avidity Biosciences (RNA) was upgraded by Wells Fargo & Company to "strong-buy".MarketBeat
- Avidity Biosciences (RNA) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $25.00 price target on the stock.MarketBeat
- Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of StockholdersPR Newswire
- The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1PR Newswire
RNA
Earnings
- 2/23/26 - Miss
RNA
Sec Filings
- 2/23/26 - Form DEFA14A
- 2/23/26 - Form 10-K
- 2/23/26 - Form 8-K
- RNA's page on the SEC website